Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts

被引：1
|
作者：
George, B. [1 ,2 ]
Kelly, K. [3 ]
Ko, A. [4 ]
Soliman, H. [5 ]
Trunova, N. [6 ]
Wainberg, Z. [7 ]
Waterhouse, D. [8 ]
O'Dwyer, P. [9 ]
Hochster, H. [10 ]
机构：
[1] Froedtert, Div Hematol & Oncol, Milwaukee, WI USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Univ Calif Davis, Ctr Comprehens Canc, Internal Med, Sacramento, CA USA
[4] Celgene Corp, Biostats, Summit, NJ USA
[5] Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA
[6] Celgene Corp, Med Affairs, Summit, NJ USA
[7] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med, Los Angeles, CA 90095 USA
[8] Oncol Hematol Care, Med Oncol, Cincinnati, OH USA
[9] Univ Penn, Abramson Canc Ctr, Med, Philadelphia, PA 19104 USA
[10] Yale Canc Ctr, Med Oncol, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw378.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1059P
引用
收藏
页数：1
相关论文
共 50 条
  • [11] FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study
    Safran, Howard
    Charpentier, Kevin
    Perez, Kimberly
    Mantripragada, Kalyan
    Austin, Trevor Clark
    Nadeem, Omar
    Lombardo, Alise
    Houlihan, Lindsay
    Fontes-Borts, Lucia
    Kolberg, Irene
    Mitchell, Kristen
    Rosati, Kayla
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [12] Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study.
    Safran, Howard
    Perez, Kimberly
    Charpentier, Kevin
    Austin, Trevor Clark
    Mantripragada, Kalyan C.
    Bishop, Kenneth D.
    Lombardo, Alise
    Houlihan, Lindsay
    Mitchell, Kristen
    Rosati, Kayla
    Martel, Diane
    Shaw, Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [13] nab-paclitaxel plus carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND. sqm study
    Spigel, D. R.
    Jotte, R. M.
    Ponce Aix, S.
    Gressot, L.
    Morgensztern, D.
    McCleod, M.
    Socinski, M. A.
    Daniel, D.
    Juan-Vidal, O.
    Kim, E. S.
    West, H. J.
    Chen, T.
    Bhore, R.
    Ong, T. J.
    Gridelli, C.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [14] nab-Paclitaxel plus carboplatin (nab-P/C) in advanced non-small cell lung cancer (NSCLC): outcomes in elderly patients (pts) with squamous (SCC) histology
    Gridelli, C.
    Ko, A.
    O'Brien, M.
    Ong, T. J.
    Socinskis, M. A.
    Postmus, P. E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S154 - S155
  • [15] Gemcitabine (G) and nab-paclitaxel (nab-P) in patients with refractory advanced pancreatic cancer (PC).
    Ernani, Vinicius
    Akunyili, Ikechukwu Immanuel
    Hosein, Peter Joel
    Macintyre, Jessica
    Lima, Caio Max S. Rocha
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [16] A PHASE I/II TRIAL OF WEEKLY NAB-PACLITAXEL (nab-P) plus GEMCITABINE(G) WITH METASTATIC PANCREATIC CANCER(MPC)
    Ikeda, Masafumi
    Ueno, Hideki
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Omuro, Yasushi
    Nakajima, Takako
    Furuse, Junji
    ANNALS OF ONCOLOGY, 2014, 25
  • [17] nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND.sqm
    Gridelli, C.
    McCleod, M.
    Morgensztern, D.
    Daniel, D. B.
    Page, R.
    Wehler, T.
    Juan, O.
    Levy, B.
    Ardizzoni, A.
    Berry, T.
    Chen, T.
    Trunova, N.
    Jotte, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [18] Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results
    Gentzler, R. D.
    Mohindra, N. A.
    Hanna, N.
    Chae, Y. K.
    Jalal, S. I.
    Hall, R.
    Villaflor, V. M.
    Reckamp, K. L.
    Koczywas, M.
    Sullivan, D.
    Wood, L.
    Patel, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 236 - 236
  • [19] Interim Results of a Phase I Study of Nivolumab plus Nab-Paclitaxel/Carboplatin in Patients with NSCLC
    Goldman, J. W.
    Waterhouse, D.
    George, B.
    O'Dwyer, P.
    Chen, T.
    Trunova, N.
    Kelly, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1959 - S1960
  • [20] nab-Paclitaxel (nab-P) plus carboplatin (C) as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC): Clinical outcomes by treatment cycle
    Gridelli, C.
    Li, L.
    O'Brien, M.
    Ong, T. J.
    Pirker, R.
    Socinski, M. A.
    Thomas, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S638 - S639
12345